Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses

Journal of Dermatological Treatment

Volumn 26, Issue 2, 2015, Pages 121-123

  Mamolo, Carla M ^a   Bushmakin, Andrew G ^a   Cappelleri, Joseph C ^a  

^a PFIZER INC   (United States)

Author keywords

Clinically important difference; Clinically important responders; ISS; Pruritus; Psoriasis; Tofacitinib

Indexed keywords

PLACEBO; TOFACITINIB; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; ITCH SEVERITY SCORE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE ASSESSMENT; TREATMENT OUTCOME; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; PSORIASIS;

DOUBLE-BLIND METHOD; HUMANS; PIPERIDINES; PRURITUS; PSORIASIS; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84930812614     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.906033     Document Type: Article

References (9)

1. Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62. doi:10.1186/1477-7525-7-62.
2. Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22:822-6.
3. Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18:227-33.
4. Papp K, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668-77.
5. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2014;28:192-203.
6. US Department of Health and Human Services [Internet]. Patientreported outcome measures: Use in medical product development to support labeling claims, 2009. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed November 29, 2013.
7. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:171-84.
8. Cappelleri JC, Bushmakin AG. Interpretation of patient-reported outcomes. Stat Methods Med Res. 2013 Feb [Epub ahead of print]. DOI: 10.1177/0962280213476377.
9. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. New York: Routledge Academic, 1988.